Autoimmune lymphoproliferative syndrome classification: Difference between revisions
m Categories |
No edit summary |
||
| Line 6: | Line 6: | ||
==Classification== | ==Classification== | ||
There is no established system for the classification of [disease name]. | |||
OR | |||
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: | |||
[Group1] | |||
[Group2] | |||
[Group3] | |||
[Group4] | |||
OR | |||
[Disease name] may be classified into [large number > 6] subtypes based on: | |||
[Classification method 1] | |||
[Classification method 2] | |||
[Classification method 3] | |||
[Disease name] may be classified into several subtypes based on: | |||
[Classification method 1] | |||
[Classification method 2] | |||
[Classification method 3] | |||
OR | |||
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic. | |||
OR | |||
If the staging system involves specific and characteristic findings and features: | |||
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2]. | |||
OR | |||
The staging of [malignancy name] is based on the [staging system]. | |||
OR | |||
There is no established system for the staging of [malignancy name]. | |||
Old nomenclature<ref name="pmid12819469">{{cite journal| author=Sneller MC, Dale JK, Straus SE| title=Autoimmune lymphoproliferative syndrome. | journal=Curr Opin Rheumatol | year= 2003 | volume= 15 | issue= 4 | pages= 417-21 | pmid=12819469 | doi= | pmc= | url= }} </ref> | Old nomenclature<ref name="pmid12819469">{{cite journal| author=Sneller MC, Dale JK, Straus SE| title=Autoimmune lymphoproliferative syndrome. | journal=Curr Opin Rheumatol | year= 2003 | volume= 15 | issue= 4 | pages= 417-21 | pmid=12819469 | doi= | pmc= | url= }} </ref> | ||
* IA - [[Fas]] | * IA - [[Fas]] | ||
Revision as of 14:10, 22 June 2021
|
Autoimmune lymphoproliferative syndrome Microchapters |
|
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune lymphoproliferative syndrome classification On the Web |
|
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome classification |
|
FDA on Autoimmune lymphoproliferative syndrome classification |
|
CDC on Autoimmune lymphoproliferative syndrome classification |
|
Autoimmune lymphoproliferative syndrome classification in the news |
|
Blogs on Autoimmune lymphoproliferative syndrome classification |
|
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome |
|
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; David Teachey, MD [2]
Overview
Classification
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
[Group1] [Group2] [Group3] [Group4] OR
[Disease name] may be classified into [large number > 6] subtypes based on:
[Classification method 1] [Classification method 2] [Classification method 3] [Disease name] may be classified into several subtypes based on:
[Classification method 1] [Classification method 2] [Classification method 3] OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features:
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name]. Old nomenclature[1]
- IA - Fas
- IB - Fas ligand
- IIA - Caspase 10
- IIB - Caspase 8
- III - unknown
- IV - Neuroblastoma RAS viral oncogene homolog
Revised nomenclature (2010)[2]
- ALPS-FAS: Fas. Germline FAS mutations. 70% of patients. Autosomal dominant. Dominant negative and haploinsufficient mutations described.[3]
- ALPS-sFAS: Fas. Somatic FAS mutations in DNT compartment.[4] 10% of patients
- ALPS-FASL: Fas ligand. Germline FASL mutations. 3 reported cases
- ALPS-CASP10: Caspase 10. Germline CASP10 mutation. 2% of patients
- ALPS-U: Undefined. 20% of patients
- CEDS: Caspase 8 deficiency state. No longer considered a subtype of ALPS but distinct disorder
- RALD: NRAS , KRAS. Somatic mutations in NRAS and KRAS in lympocyte comparment. No longer considered a subtype of ALPS but distinct disesase.
References
- ↑ Sneller MC, Dale JK, Straus SE (2003). "Autoimmune lymphoproliferative syndrome". Curr Opin Rheumatol. 15 (4): 417–21. PMID 12819469.
- ↑ Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ; et al. (2010). "Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop". Blood. 116 (14): e35–40. doi:10.1182/blood-2010-04-280347. PMC 2953894. PMID 20538792.
- ↑ Kuehn HS, Caminha I, Niemela JE, Rao VK, Davis J, Fleisher TA; et al. (2011). "FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome". J Immunol. 186 (10): 6035–43. doi:10.4049/jimmunol.1100021. PMID 21490157.
- ↑ Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur AM; et al. (2004). "Autoimmune lymphoproliferative syndrome with somatic Fas mutations". N Engl J Med. 351 (14): 1409–18. doi:10.1056/NEJMoa040036. PMID 15459302.